Sun Pharma announces approval to mkt Tessalon

20864 Investors following Sun Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sun Pharma announces approval to mkt Tessalon

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market a generic version of Forest Lab’s Tessalon®, benzonatate capsules.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Sun Pharma announces approval to mkt generic Cerebyx Sun Pharma announces approval to mkt generic Ethyol Sun Pharma gets approval for generic Gemzar injection ALSO READ See latest News about Sun Pharma See previous management interviews See what other Experts & Brokerages are saying about Sun Pharma Sun Pharma BSE | NSE 25/05/12 Are Mutual Funds betting on Sun Pharma?

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market a generic version of Forest Lab's Tessalon®, benzonatate capsules.

Benzonatate USP capsules are therapeutically equivalent to Forest Lab's Tessalon®, and are available in two strengths: capsules containing 100 mg and 200 mg benzonatate USP.

Benzonatate has annual sales of approximately USD 40 million in the US.

Benzonatate is an antitussive, used to relieve cough due to the common cold, bronchitis, pneumonia, or other lung infections.

This product will reach market shortly.

Sourced From: Sun Pharmaceutical Industries Ltd